CION Ameerpet
Pancreatic Cancer · Diagnosis & Tests · Reviewed by CION Oncologists
Pancreatic cancer grade and differentiation — what your report is telling you
Grade is one line on a pathology report, and it worries people out of all proportion to what it actually decides. It describes how abnormal the cells look under the microscope — not how far the disease has spread, and not whether an operation is possible. Here is what each word means, and how much weight it really carries.
- Grade is about appearance, not extent — it says how abnormal the cells look, never how far the cancer has travelled.
- Well, moderately or poorly differentiated — three bands on one scale, defined by the WHO classification your pathologist works to.
- It does not decide the operation — whether surgery is possible comes from the scan and the vessel anatomy, not the grade.
- It can change on a later report — a needle sees a fragment; the whole specimen sometimes tells a fuller story.
17+
Cancer Specialists
on Panel
on Panel
35+
Centres Across
Telangana & AP
Telangana & AP
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Start here
What Tumour Grade Actually Describes
A pathologist is answering one narrow question when they report the pancreatic cancer grade: under the microscope, how closely do these cells still resemble the normal pancreatic tissue they grew out of? Cells that still line up into recognisable glands, still make mucin, still look organised, are called well differentiated. Cells that have lost that resemblance — crowded, disordered, dividing quickly, barely forming a gland at all — are called poorly differentiated. Grade is the word for where your tumour sits on that scale. Differentiation is the property being measured.
Grade is not stage, and the two get confused constantly, often inside the same conversation. Stage describes how far the disease has travelled: the size of the primary, whether lymph nodes are involved, whether there are deposits further away. It comes mainly from scans, and it drives the biggest decision of all — whether an operation is on the table. Grade describes how the cells look and behave, comes from tissue rather than imaging, and says nothing about extent. A small tumour can be poorly differentiated. A well differentiated pancreatic cancer can already be advanced. They are two separate axes, and you need both to understand where you stand.
There is a second source of confusion, which is that pancreatic reports use two different grading systems depending on what kind of tumour is being described. Pancreatic ductal adenocarcinoma, the common form, is graded on architecture — how much of the tumour still forms glands, how much mucin the cells produce, how many are caught in the act of dividing. A pancreatic neuroendocrine tumour is graded on a different rule altogether: chiefly how fast the cells are dividing, expressed as a mitotic count and a proliferation index. So a tumour grade pancreas report can carry the same words, grade 1 through grade 3, and mean something quite different depending on which tumour type it belongs to.
Grade cannot be read off a CT or an MRI. It needs cells, which means a biopsy sample or, where an operation goes ahead, the removed specimen. That is also why the grade occasionally shifts between one report and the next: a needle takes a fragment, and pancreatic tumours are not uniform throughout. The rest of the vocabulary sitting on the same page — margins, nodes, perineural invasion, tumour type — is unpacked in understanding your pancreatic cancer pathology report.
Did you know? The framework your pathologist works to is the World Health Organization classification of tumours of the digestive system, which defines these words rather than leaving them to individual judgement. For pancreatic ductal adenocarcinoma it sets grade by how much of the tumour still forms glands, alongside mucin production and how many cells are dividing, reported as well, moderately or poorly differentiated. For neuroendocrine neoplasms the same WHO series uses a separate rule based on the rate of cell division, which sorts tumours into grade 1, grade 2 and grade 3 and, importantly, distinguishes a well-differentiated neuroendocrine tumour from a poorly differentiated neuroendocrine carcinoma — a different disease, not simply a higher grade. NCCN guidance for pancreatic adenocarcinoma and for neuroendocrine tumours both refer back to these definitions, which is why the same words appear on reports issued anywhere in the world.
Translating the report
The Grade Words You Will See, and What Each Means
Your report may use the words, the G codes, or both. They are the same thing written two ways.
| Term in the report | What the pathologist saw | What it generally suggests | The honest caveat |
|---|---|---|---|
| Well differentiated (G1) | Cells still form clear glands and closely resemble the normal duct lining they arose from | A tumour whose cells are still behaving somewhat like their tissue of origin | Says nothing about size, nodes or spread — well differentiated disease can still be advanced |
| Moderately differentiated (G2) | Gland formation partly preserved and partly lost; the band most pancreatic adenocarcinomas fall into | An intermediate pattern, between the two extremes | Because it is the commonest grade, it rarely changes the plan on its own |
| Poorly differentiated (G3) | Little or no gland formation; crowded, disordered cells with frequent division | A more aggressive pattern of behaviour | Not a verdict. It is one input among several, and it rules nothing out by itself |
| Grade cannot be assessed (GX) | Too little tissue, or a sample crushed or degraded before it reached the slide | Nothing at all — the question was not answerable on this sample | An incomplete answer, not a bad one. Grade is often assigned later on a larger specimen |
| Neuroendocrine, grade 1 to grade 3 | Graded on how fast the cells divide, using a mitotic count and a proliferation index, not on gland formation | How quickly a neuroendocrine tumour is likely to move | A different scale from the adenocarcinoma one. The same digit does not mean the same thing |
Why it matters, and how much
What Your Grade Changes, and What It Does Not
Grade is genuinely useful. It is also routinely given more weight than it deserves by someone reading their own report at midnight.
Not the operation
Whether surgery is possible is a separate question
Resectability is decided on the scan — where the tumour sits in relation to the arteries and veins behind the pancreas. A poorly differentiated tumour anatomically clear of those vessels is still operable, and a well differentiated one wrapped around an artery is still not.
Systemic treatment
It feeds into the chemotherapy conversation
Grade is one of the things weighed when deciding how intensive systemic treatment should be and in what order it comes, alongside your stage, your fitness and what the imaging shows. An input to that discussion, never the whole of it.
Neuroendocrine tumours
Here grade carries far more weight
In a pancreatic neuroendocrine tumour, grade comes close to decisive. It separates tumours that may be watched or treated gently from those needing systemic treatment quickly, and it influences whether receptor imaging will be informative at all.
Outlook
Grade shifts the picture, it does not set it
Differentiation is one of several things that shape what to expect, and a poor predictor on its own. What it does and does not tell you is set out honestly in how grade and differentiation affect pancreatic cancer outlook.
Sampling
A needle sees a fragment, not the tumour
Grade on a small biopsy can differ from grade on the whole specimen after an operation, because these tumours vary within themselves. A changed grade on a later report is usually a fuller look, not an error in the first one.
The plan
It is read with everything else, never alone
At a tumour board the grade sits next to the stage, the vessel anatomy, the CA 19-9 trend, your other health conditions and what you want. The routes that follow are set out in pancreatic cancer treatment in Hyderabad.
If one word on your report has been keeping you awake, bring the report itself rather than the summary letter. A free 45-minute consultation is usually enough to put it back in proportion. Book a free consultation or call 1800 202 8726.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
A Grade Is One Line in a Longer Report
It matters, but it never decides a plan on its own. We put it next to everything else.
What actually happens
How Your Grade Is Arrived At, and Who Does What
-
Tissue has to be obtained first
No scan can grade a tumour. Most often the sample comes from an endoscopic ultrasound with a fine-needle biopsy. CION does not run an endoscopy unit; we arrange that with specialist gastroenterology and endoscopy partners, and that part of your care may be billed there.
Coordinated with specialist endoscopy partners -
A pathologist reads the slides
The specimen goes to the histopathology laboratory attached to the centre that took it. The pathologist confirms the tumour type, then assigns the grade using the WHO criteria for that type — gland formation for adenocarcinoma, rate of division for a neuroendocrine tumour.
Coordinated with the laboratory handling the specimen -
Your oncologist reads it against everything else
The grade only becomes useful next to your scans, your bloods and your CA 19-9. We open the report with you rather than paraphrasing it, and say plainly which lines change the plan and which are simply part of a standard template.
In-house at CION -
The case goes to a tumour board
Medical and radiation oncology look at the pathology and the imaging together, with surgical input from our partner hepatobiliary centres where an operation is in question. No single line of a report decides a plan on its own, and grade is not the exception.
In-house at CION, with partner surgical input -
If an operation goes ahead, the grade is confirmed on the whole specimen
A resection gives the pathologist the entire tumour rather than a core, so the grade can be confirmed or revised, and the margins and nodes reported alongside it. Pancreatic surgery is coordinated with specialist hepatobiliary partners and may be billed there.
Coordinated with specialist HPB partners -
What it means for you is explained, and written down
You should leave knowing what your grade is, what it changes, what it does not change, and what happens next. If a grade has been revised between reports, we explain why, rather than letting you find the difference yourself.
In-house at CION
Being straight about it
What CION Does With Your Grade, and What Is Coordinated Elsewhere
This matters practically, because it decides where you travel and who invoices you. Getting the tissue is not something we do ourselves. Endoscopic ultrasound and biopsy, ERCP and any biliary or duodenal stenting, staging laparoscopy, coeliac plexus block and all pancreatic surgery are coordinated with specialist hepatobiliary, gastroenterology and endoscopy partners, and the histopathology laboratory that grades the specimen usually sits with them. PET-CT and receptor imaging are coordinated with partner nuclear-medicine centres. Each of those parts may be billed by the partner rather than by us, and we will tell you that before anything is booked.
What happens at CION is everything the grade is then used for. Reading the report and explaining it. Tumour-board planning. Chemotherapy, whether before surgery, after it, or as the main treatment. Maintenance treatment of the PARP-inhibitor class where a BRCA-type fault is found, and immunotherapy where the tumour is mismatch-repair deficient. Systemic therapy for neuroendocrine tumours, including somatostatin-analogue-class treatment. Radiation, chemoradiation and SBRT. Pancreatic-protocol CT, MRI and MRCP, CA 19-9 and routine bloods, ordered and reported by us. Genetic counselling where the family history warrants it, nutrition and pancreatic enzyme support, pain and psycho-oncology care, and long-term follow-up. All of that is delivered in-house across 35+ centres.
- A free 45-minute consultation, with the pathology report read out with you line by line rather than summarised back at you.
- A plain answer on what your grade does and does not change about your own plan, including where it changes nothing.
- A second look at the report where the grade could not be assessed, or where a repeat sample would genuinely add something.
- A written split of what a partner centre bills and what CION bills, before any biopsy or operation is arranged.
- Aarogyasri, NTR Vaidya Seva and insurance routes checked against each part of the pathway, not only the treatment.
- Systemic therapy, radiation, nutrition and supportive care delivered in-house — the options are set out in pancreatic cancer treatment in Hyderabad.
- The whole picture in one place, in our complete guide to pancreatic cancer.
Bring the pathology report and the scan discs, not just the discharge summary. Those two together are usually enough for a specialist to tell you where you stand. Book a free consultation or call 1800 202 8726.
Take the next step
Understand the Report Before It Frightens You
Most of the fear in a pathology report comes from words nobody has explained. We explain them.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
Pancreatic cancer grade — your questions answered
What does the grade of a pancreatic cancer actually mean?
Grade is the pathologist's description of how abnormal the cells look under the microscope, and how far they have drifted from the normal pancreatic tissue they came from. Cells that still form recognisable glands and still resemble their tissue of origin are reported as well differentiated. Cells that have lost that structure, look disordered and are dividing quickly are reported as poorly differentiated, with a middle band called moderately differentiated. It is a statement about how the tumour is behaving at a cellular level, not about how big it is or where it has reached. Grade comes from tissue, which means a biopsy or a surgical specimen, and it cannot be worked out from a CT or an MRI however good the scan is.
Is grade the same thing as stage?
No, and this is the single commonest mix-up. Stage answers how far the disease has spread: the size of the tumour, whether lymph nodes are involved, whether there are deposits elsewhere in the body. It is worked out mainly from imaging and it drives the largest decision of all, which is whether an operation is possible. Grade answers a completely different question, which is how abnormal the cells look down the microscope. The two do not move together in any reliable way. A small tumour can be poorly differentiated, and a well differentiated pancreatic cancer can already be advanced. You need both pieces of information, from two different sources, before your situation makes sense.
What does well differentiated pancreatic cancer mean on my report?
It means the tumour cells still look and organise themselves much like the normal cells of the pancreatic duct lining. They are still forming glands, still producing mucin, and the overall architecture is still recognisable. In broad terms, well differentiated tumours tend to behave less aggressively than poorly differentiated ones, which is why the word is generally taken as reassuring. That reassurance has a limit worth stating plainly. Differentiation says nothing about size, nodes or spread, so a well differentiated tumour can still be locally advanced or already spread when it is found. It is one favourable feature among many that are weighed together, not a grading of how serious your situation is overall.
Does a low grade mean my outlook is better?
It is one of several things that shift the picture, and on its own it is a weak predictor. What matters far more is whether the tumour can be removed completely, whether lymph nodes are involved, how well you tolerate systemic treatment, and how the disease responds once treatment starts. Grade sits alongside all of that rather than above it. Published outlook figures for pancreatic cancer are also harder to read than they look, because they average across very different situations and lump together tumour types that behave nothing like each other. We would rather talk that through with your own report and scans in front of us than quote a number at you. The grade and prognosis page on this site goes into that in detail.
Why has my grade changed between two reports?
This happens more often than people expect, and it is usually not a mistake. A fine-needle biopsy takes a small core, and pancreatic tumours are not uniform throughout, so one area can look more differentiated than another. When an operation removes the whole tumour, the pathologist sees all of it and grades the worst-looking area, which can move the grade up or occasionally down. A report that first said the grade could not be assessed is a different situation again, and simply means there was too little usable tissue on that sample. If your grade has changed, ask which specimen each report came from. That single question usually explains the difference completely.
What does CION do about grade, and what happens at the first visit?
The first visit is a free 45-minute consultation, and it is a reading session as much as a clinic appointment. Bring the pathology report and the scan discs. We open the report with you, say what the grade is, what it changes about your plan and what it does not, and separate the lines that matter from the standard template around them. The biopsy itself, any endoscopic procedure and all pancreatic surgery are coordinated with specialist hepatobiliary, gastroenterology and endoscopy partners and may be billed there, and we tell you that split in writing before anything is booked. Chemotherapy, radiation and SBRT, imaging and bloods, genetic counselling, nutrition and enzyme support, pain and psycho-oncology care and long-term follow-up are delivered by CION across 35+ centres.
Medical disclaimer: This page explains what tumour grade and differentiation describe on a pancreatic cancer pathology report and how they are used, and is reviewed by a CION medical oncologist with reference to NCCN guidance and the World Health Organization classification of tumours of the digestive system and of neuroendocrine neoplasms. It is general information and not a substitute for an individual pathological or oncological opinion; what your own grade means for your plan depends on your tumour type, stage, imaging and general health, and must be decided with your treating team. Reading and acting on the report, tumour-board planning, chemotherapy, maintenance and immunotherapy of the classes described, systemic therapy for neuroendocrine tumours, radiation, chemoradiation and SBRT, pancreatic-protocol CT, MRI and MRCP, CA 19-9 and bloods, genetic counselling, nutrition and pancreatic enzyme support, pain and psycho-oncology care and survivorship follow-up are delivered by CION. Endoscopic ultrasound and biopsy, the histopathology laboratory handling the specimen, ERCP and biliary or duodenal stenting, staging laparoscopy, coeliac plexus block and all pancreatic surgery are coordinated with specialist hepatobiliary, gastroenterology and endoscopy partner centres, and PET-CT and receptor imaging with partner nuclear-medicine centres; each of these may be billed there.